source
- Biomea posts modest Phase 1 results for oral GLP-1 drug, shares slideBiomea Fusion released Phase 1 data for its oral small‑molecule GLP‑1 agonist BMF‑650, positioning the program as a potential partner opportunity that could separate efficacy from gastrointestinal…
- Verdiva Bio halts phase 2 oral GLP-1 trial after enrolling only eight participantsVerdiva Bio announced it is ending its phase 2 study of VRB-101, a once‑weekly oral GLP‑1 candidate, after the trial fell far short of its enrollment target. The study was intended to evaluate swi…